Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
The program was put on hold in December 2020 following a patient report, but this was lifted in April 2021. million price tag. The post Can gene therapies for haemophilia defend their high price tags? CSL Behring has a commercialisation and license agreement to develop EtranaDez. million ($1.8 million at the time).
Let's personalize your content